首页> 外文OA文献 >Dual-functional transdermal drug delivery system with controllable drug loading based on thermosensitive poloxamer hydrogel for atopic dermatitis treatment
【2h】

Dual-functional transdermal drug delivery system with controllable drug loading based on thermosensitive poloxamer hydrogel for atopic dermatitis treatment

机译:基于热敏泊洛沙姆水凝胶的可控制载药量的双功能透皮给药系统,用于特应性皮炎的治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The treatment of atopic dermatitis (AD) has long been viewed as a problematic issue by the medical profession. Although a wide variety of complementary therapies have been introduced, they fail to combine the skin moisturizing and drug supply for AD patients. This study reports the development of a thermo-sensitive Poloxamer 407/Carboxymethyl cellulose sodium (P407/CMCs) composite hydrogel formulation with twin functions of moisture and drug supply for AD treatment. It was found that the presence of CMCs can appreciably improve the physical properties of P407 hydrogel, which makes it more suitable for tailored drug loading. The fabricated P407/CMCs composite hydrogel was also characterized in terms of surface morphology by field emission scanning electron microscopy (FE-SEM), rheological properties by a rheometer, release profile in vitro by dialysis method and cytotoxicity test. More importantly, the findings from transdermal drug delivery behavior revealed that P407/CMCs showed desirable percutaneous performance. Additionally, analysis of cytotoxicity test suggested that P407/CMCs composite hydrogel is a high-security therapy for clinical trials and thus exhibits a promising way to treat AD with skin moisturizing and medication.
机译:异位性皮炎(AD)的治疗长期以来一直被医学界视为有问题的问题。尽管已经引入了各种各样的补充疗法,但是它们不能将皮肤保湿和药物供应结合起来用于AD患者。这项研究报告了热敏性泊洛沙姆407 /羧甲基纤维素钠(P407 / CMCs)复合水凝胶制剂的开发,该制剂具有双重水分和药物供应功能,可用于AD治疗。发现CMC的存在可以明显改善P407水凝胶的物理性质,这使其更适合于定制的药物负载。还通过场发射扫描电子显微镜(FE-SEM),表面流变仪的流变特性,透析方法和细胞毒性试验的体外释放曲线,对制备的P407 / CMCs复合水凝胶进行了表面形态表征。更重要的是,从透皮给药方式的发现表明,P407 / CMCs具有理想的经皮性能。此外,细胞毒性试验的分析表明,P407 / CMCs复合水凝胶是一种用于临床试验的高安全性疗法,因此显示了通过皮肤保湿和药物治疗AD的有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号